fda warning letters compounding semaglutide september 2025 The sent a letter this month to Novo Nordisk, alleging the drugmaker failed to report, in a timely manner, potential side effects in patients who took its popular medications containing Navigating Compounded Semaglutide: What Health

Several factors contribute: Insurance networks - Joining insurance networks requires contracting, credentialing, and claims submission infrastructure Coverage limitations - Many insurance plans do not cover GLP-1 medications for weight loss (vs

Key Points for Practice All adults should be tested for diabetes beginning at 45 years of age

Systematic review of indexing databases like the NCBI PubMed database confirms that gastrointestinal events peak during active titration schedules

In propensity-matched analyses comparing patients with IBD to those without IBD receiving GLP-1 RAs, weight loss outcomes were broadly similar between groups

It is also, based on what I have been able to find, very unlikely to be working

Semaglutide is much more costly compared with bariatric surgery